Tim said "And we now have sufficient cash to take us well into the third quarter but that doesn't include any potential proceeds from further partnering transactions and as John will be telling you later there are a number of potential deals in the pipeline at the moment. Parkinson's disease follow-up program, as John has said, that we're likely to see the first patient dosed and during the third quarter of 2016 and we will file for the OXB-202 which is the Corneal graft program in the second half of the year. And by the end of the year we will have the preclinical study results from OXB-302 which is the CAR-T 5T4 program.
In terms of partnered products, Novartis have indicated that they will have their study results from CTL-019 in the second half of the year, and they've also indicated that they will file that BLA submission either in very end of 2016 or early 2017. And we believe those items of news flow will help us and if all goes all, it holds out the prospect of -- for us a commercial supply agreement with Novartis to supply the commercial launch of CTL-019. We're making great progress at the moment in coming up with a bioreactor process. We are hoping shortly to move into 200 liter bioreactors with a serum-free suspension process. This offers the prospect of improved yield but also improved volumes .we have every confidence that we will gain third contracts with new partners which will not only give us a short-term benefit of bioprocessing and process development fees but also a long-term economic interest in the product candidates that they bring to us. CAR-T-5T4 is not the only preclinical thing that we're looking at. Is CAR-T-5T4that something we should do by ourselves or is it something we should try and partner with a company who is in a better place in the oncology area for example to work with us? debt facility is repayable in 2022, we are under no obligation to repay it earlier but we can repay earlier if we see the opportunity.
